Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia
Background. The increasing number of registered biosimilars of monoclonal antibodies (mAbs) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers. Therefore, investigating their economic effect appears highly relevant.Objective: To examine the impac...
Saved in:
Main Authors: | A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2025-05-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/1145 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First available biosimilar monoclonal antibodies
by: Zh. I. Avdeeva, et al.
Published: (2018-02-01) -
Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
by: V. V. Smirnov, et al.
Published: (2023-06-01) -
Beyond cost: a value-based framework for biosimilar procurement in emerging markets – the Thai experience
by: Anunchai Assawamakin, et al.
Published: (2025-12-01) -
International standards for monoclonal antibodies for assessing the biological activity of medicines: A status update
by: L. A. Gayderova, et al.
Published: (2023-12-01) -
Study on the monoclonal antibody to chlorpyrifos
by: JIN Ren-yao, et al.
Published: (2006-11-01)